ArticleJournal of inflammation research2025
Shared and Distinctive Inflammation-Related Protein Profiling in Idiopathic Inflammatory Myopathy with/without Anti-MDA5 Autoantibodies.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial Intelligence in Neuromuscular Diseases: Opportunities for a Data-Scarce Field.Neurology and therapy · 2026Review
- Recent advances in immunological mechanisms and murine disease models of idiopathic inflammatory myopathies.Inflammation and regeneration · 2025Review
- Clinical and Molecular Insights Into Anti-MDA5 Antibody-Positive Dermatomyositis: A Single-Center Retrospective and Transcriptomic Study.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Due to the heterogeneous nature of the diseases, treatment efficacy and prognosis vary for idiopathic inflammatory myopathy (IIM) patients with different myositis specific autoantibodies (MSAs). This study aimed to investigate the inflammation-related protein profiling of IIM patients with different MSAs. In addition, the shared and distinctive inflammation-related protein profiling in IIM with/without anti-MDA5 autoantibodies. Methods: Seventy-seven patients with IIM of different MSAs and 53 gender/age matched healthy controls (HCs) were enrolled in this study. Ninety-two inflammation-related proteins were detected by Olink proteomics. We identified differentially expressed proteins (DEPs), and performed gene set enrichment analysis and KEGG pathway analysis. In addition, correlation between DEPs and serological parameters were performed. The least absolute shrinkage and selection operator (Lasso) regression algorithm of machine learning was used to screen biomarkers related to anti-MDA5+ DM. Results: Compared with HCs, 36 inflammation-related proteins were identified as DEPs. The top 10 DEPs were CXCL10, CXCL11, CXCL9, CXCL8, S100A12, IL-6, CCL2, CCL8, IL-10 and CCL3. The inflammation-related proteins and cytokine-cytokine receptor interaction pathway were more strikingly expressed in patients with anti-MDA5+ DM patients than in anti-MDA5- IIM patients. In addition, multiple DEPs correlated with serum ferritin, KL-6, muscle enzymes. For the first time, we established that a multi-factor panel comprising CX3CL1, IL-17C, IL-18R1, CCL20, and TNF (AUC = 0.824) serves as a highly efficient diagnostic biomarker for anti-MDA5+ DM. Conclusion: Plasma profiling revealed that inflammation and inflammatory pathways were extremely elevated in patients with IIM, especially in patients with anti-MDA5 autoantibodies. The shared and distinctive inflammation-related protein signature was demonstrated in patients with/without anti-MDA5 autoantibodies. The expression of CX3CL1 was significantly higher in anti-MDA5+ DM than in patients without anti-MDA5 autoantibodies. In addition, CX3CL1 correlated with ESR, serum ferritin, CK enzymes and disease activity, indicating that CX3CL1 participated in inflammation status of anti-MDA5+ DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.